StockData
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. (TARS) stock

TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$78.20−0.48 (-0.61%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%

Tarsus Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Tarsus Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was $74.16M. For fiscal 2025 it was -$12.45M. The highest annual figure on record is $3.75M in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.45M–
FY2024Dec 31, 2024-$83.03M–
FY2023Dec 31, 2023-$117.49M–
FY2022Dec 31, 2022-$49.03M-1408.2%
FY2021Dec 31, 2021$3.75M–
FY2020Dec 31, 2020-$21.14M–
FY2019Dec 31, 2019-$3.67M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$61.22M–
Q1 FY2026Mar 31, 2026-$24.65M–
Q4 FY2025Dec 31, 2025$19.33M–
Q3 FY2025Sep 30, 2025$18.26M–
Q2 FY2025Jun 30, 2025-$29.39M–
Q1 FY2025Mar 31, 2025-$20.65M–
Q4 FY2024Dec 31, 2024-$22.18M–
Q3 FY2024Sep 30, 2024-$8.65M–
Q2 FY2024Jun 30, 2024-$14.40M–
Q1 FY2024Mar 31, 2024-$37.79M–
Q4 FY2023Dec 31, 2023-$39.34M–
Q3 FY2023Sep 30, 2023-$32.36M–
Q2 FY2023Jun 30, 2023-$23.83M–
Q1 FY2023Mar 31, 2023-$21.97M–
Q4 FY2022Dec 31, 2022-$10.87M–
Q3 FY2022Sep 30, 2022-$18.61M-361.7%
Q2 FY2022Jun 30, 2022-$4.26M-120.7%
Q1 FY2022Mar 31, 2022-$15.29M–
Q4 FY2021Dec 31, 2021-$12.12M–
Q3 FY2021Sep 30, 2021$7.11M–
Q2 FY2021Jun 30, 2021$20.55M–
Q1 FY2021Mar 31, 2021-$11.79M–
Q4 FY2020Dec 31, 2020-$10.01M–
Q3 FY2020Sep 30, 2020-$6.57M–
Q2 FY2020Jun 30, 2020-$2.56M–
Q1 FY2020Mar 31, 2020-$2.00M–
Q4 FY2019Dec 31, 2019-$806.00K–

More Tarsus Pharmaceuticals figures

See a number that looks wrong?